A Phase 3 interventional study of Etrasimod and Placebo in Ulcerative Colitis, sponsored by Arena Pharmaceuticals. Completed at 315 sites in 40 countries. Open to participants aged 16 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-12-20.
Sponsored by Arena Pharmaceuticals (part of Pfizer) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing etrasimod in Colitis, Ulcerative — 3 open to participants now, 5 under way, 2 of them phase 3. etrasimod · Colitis, Ulcerative.
Among the 12 studies testing etrasimod in Colitis, Ulcerative, this one is the 2nd largest by enrollment, is one of 3 that started in 2019, is one of 5 in phase 3, and was the 3rd registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →3 of the 12 studies testing etrasimod in Colitis, Ulcerative are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in United States, Australia, Canada and 7 more countries
Ages 2–11
Pfizer · Sites in United States, Japan, Poland and 2 more countries
Ages 12–17
Sir Run Run Shaw Hospital
Ages 18–100
By country, each count listing its studies:
etrasimod: first FDA approval 2023 (VELSIPITY), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 16 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 3 started in 2019.
This study's enrollment of 433 is above the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 195 across the 12 interventional studies. Of the 7 that completed or were terminated, 7 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 12 have an industry lead sponsor. The 4 most frequent:
This study is registered under Arena Pharmaceuticals, one of the names counted as Pfizer. Under that name alone:
Arena Pharmaceuticals is the lead sponsor of 17 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
42 studies in Colitis, Ulcerative by Pfizer: 3 open now, 7 under way, 2 of them phase 3. Of 32 finished, 26 (81%) have results posted.
Among the 42 studies in Colitis, Ulcerative by Pfizer, this one is the 6th largest by enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2019, is one of 9 in phase 3, and was the 20th registered.
Pfizer’s Colitis, Ulcerative studies by the year they started, since 2005.
1 of the studies testing etrasimod in Colitis, Ulcerative that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07782242Sir Run Run Shaw HospitalComaprison of Efficacy and Safety Between Etrasimod vs Mesalazine in Chinese Adults With Active UC | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing etrasimod in Colitis, Ulcerative, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 42 in Colitis, Ulcerative:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether oral etrasimod is a safe and effective treatment for moderately to severely active ulcerative colitis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Drug: Etrasimod
Drug: Placebo
Etrasimod 2 mg tablet by mouth, once daily up to 52 weeks of treatment
Also known as: APD334
Etrasimod matching placebo tablet by mouth, once daily up to 52 weeks of treatment
Percentage of Participants Achieving Clinical Remission at Week 12
Clinical remission was based on the modified Mayo score (MMS). The MMS is a composite score of 3 assessments consisting of participant-reported symptoms using daily eDiary and centrally read endoscopy: stool frequency (SF), rectal bleeding (RB) and endoscopic score (ES). Clinical remission was defined as SF subscore = 0 (or = 1 with a ≥ 1-point decrease from Baseline), RB subscore = 0, and ES ≤ 1 (excluding friability). Each component subscore ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.
Time frame: At Week 12
Percentage of Participants Achieving Clinical Remission at Week 52
Clinical remission was based on the MMS which is a composite score of 3 assessments: SF, RB and ES. Clinical remission was defined as SF subscore = 0 (or = 1 with a ≥ 1-point decrease from Baseline), RB subscore = 0, and ES ≤ 1 (excluding friability). Each component subscore ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.
Time frame: At Week 52
Percentage of Participants Achieving Endoscopic Improvement at Week 12
Endoscopic improvement was defined as an ES ≤ 1 (excluding friability). The ES ranged from 0 to 3 (where 0 = normal/inactive disease and 3 = severe disease).
Time frame: At Week 12
Percentage of Participants Achieving Endoscopic Improvement at Week 52
Endoscopic improvement was defined as an ES ≤ 1 (excluding friability). The ES ranged from 0 to 3 (where 0 = normal/inactive disease and 3 = severe disease).
Time frame: At Week 52
Percentage of Participants Achieving Symptomatic Remission at Week 12
Symptomatic remission was defined as an SF subscore = 0 (or = 1 with a ≥ 1-point decrease from Baseline) and RB subscore = 0. The SF subscore ranged from 0 to 3 (where 0 = normal number of stools and 3 = at least 5 stools more than normal) and RB subscore ranged from 0 to 3 (where 0 = no blood and 3 = blood alone passes). Higher scores indicate more severe disease.
Time frame: At Week 12
Percentage of Participants Achieving Symptomatic Remission at Week 52
Symptomatic remission was defined as an SF subscore = 0 (or = 1 with a ≥ 1-point decrease from Baseline) and RB subscore = 0. The SF subscore ranged from 0 to 3 (where 0 = normal number of stools and 3 = at least 5 stools more than normal) and RB subscore ranged from 0 to 3 (where 0 = no blood and 3 = blood alone passes). Higher scores indicate more severe disease.
Time frame: At Week 52
Percentage of Participants With Mucosal Healing at Week 12
Mucosal healing was defined as an ES ≤ 1 (excluding friability) with histologic remission measured by a Geboes Index score \< 2.0. The ES ranged from 0 to 3 (where 0 = normal/inactive disease and 3 = severe disease). The Geboes score grading system is a validated score for evaluating histologic disease activity in UC as follows: grade 0 = structural and architectural changes; grade 1 = chronic inflammatory infiltrate; grade 2 = lamina propria neutrophils and eosinophils; grade 3 = neutrophils in the epithelium; grade 4 = crypt destruction; grade 5 = erosions or ulceration. A higher Geboes score indicates more severe disease.
Time frame: At Week 12
Percentage of Participants With Mucosal Healing at Week 52
Mucosal healing was defined as an ES ≤ 1 (excluding friability) with histologic remission measured by a Geboes Index score \< 2.0. The ES ranged from 0 to 3 (where 0 = normal/inactive disease and 3 = severe disease). The Geboes score grading system is a validated score for evaluating histologic disease activity in UC as follows: grade 0 = structural and architectural changes; grade 1 = chronic inflammatory infiltrate; grade 2 = lamina propria neutrophils and eosinophils; grade 3 = neutrophils in the epithelium; grade 4 = crypt destruction; grade 5 = erosions or ulceration. A higher Geboes score indicates more severe disease.
Time frame: At Week 52
Percentage of Participants Achieving Corticosteroid-free Clinical Remission at Week 52
Corticosteroid-free clinical remission was defined as an SF subscore = 0 (or = 1 with a ≥ 1-point decrease from Baseline), RB subscore = 0, ES ≤ 1 (excluding friability), and have not received corticosteroids for ≥ 12 weeks in the 40-Week Treatment Period. Each component subscore ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.
Time frame: At Week 52
Percentage of Participants Achieving Sustained Clinical Remission at Both Weeks 12 and 52
Sustained clinical remission was defined as an SF subscore = 0 (or = 1 with a ≥ 1-point decrease from Baseline), RB subscore = 0, and ES ≤ 1 (excluding friability) at both Week 12 and Week 52. Each component subscore ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.
Time frame: At Weeks 12 and 52
Percentage of Participants Achieving Clinical Response at Week 12
Clinical response was based on the MMS which is a composite score of 3 assessments: SF, RB and ES. Clinical response was defined as a ≥ 2-point and ≥ 30% decrease from Baseline MMS, and a ≥ 1-point decrease from Baseline in RB subscore or an absolute RB subscore ≤ 1. Each component subscore ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.
Time frame: At Week 12
Percentage of Participants Achieving Clinical Response at Week 52
Clinical response was based on the MMS which is a composite score of 3 assessments: SF, RB and ES. Clinical response was defined as a ≥ 2-point and ≥ 30% decrease from Baseline MMS, and a ≥ 1-point decrease from Baseline in RB subscore or an absolute RB sub-score ≤ 1. Each component subscore ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.
Time frame: At Week 52
Percentage of Participants Achieving Clinical Response at Both Weeks 12 and 52
Clinical response was based on the MMS which is a composite score of 3 assessments: SF, RB and ES. Clinical response was defined as a ≥ 2-point and ≥ 30% decrease from Baseline MMS, and a ≥ 1-point decrease from Baseline in RB subscore or an absolute RB subscore ≤ 1. Each component subscore ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.
Time frame: At Weeks 12 and 52
Percentage of Participants With Mucosal Healing at Both Weeks 12 and 52
Mucosal healing was defined as an ES ≤ 1 (excluding friability) with histologic remission measured by a Geboes Index score \< 2.0. The ES ranged from 0 to 3 (where 0 = normal/inactive disease and 3 = severe disease). The Geboes score grading system is a validated score for evaluating histologic disease activity in UC as follows: grade 0 = structural and architectural changes; grade 1 = chronic inflammatory infiltrate; grade 2 = lamina propria neutrophils and eosinophils; grade 3 = neutrophils in the epithelium; grade 4 = crypt destruction; grade 5 = erosions or ulceration. A higher Geboes score indicates more severe disease.
Time frame: At Weeks 12 and 52
Percentage of Participants Achieving Endoscopic Normalization at Week 12
Endoscopic normalization was defined as an ES = 0. The ES ranged from 0 to 3 (where 0= normal/inactive disease and 3= severe disease).
Time frame: At Week 12
Percentage of Participants Achieving Endoscopic Normalization at Week 52
Endoscopic normalization was defined as an ES = 0. The ES ranged from 0 to 3 (where 0= normal/inactive disease and 3= severe disease).
Time frame: At Week 52
Percentage of Participants Achieving Endoscopic Normalization at Both Weeks 12 and 52
Endoscopic normalization was defined as an ES = 0. The ES ranged from 0 to 3 (where 0= normal/inactive disease and 3= severe disease).
Time frame: At Weeks 12 and 52
Percentage of Participants Achieving Symptomatic Remission by Study Visit
Symptomatic remission was defined as an SF subscore = 0 (or = 1 with a ≥ 1-point decrease from Baseline) and RB subscore = 0. The SF subscore ranged from 0 to 3 (where 0 = normal number of stools and 3 = at least 5 stools more than normal) and RB subscore ranged from 0 to 3 (where 0 = no blood and 3 = blood alone passes). Higher scores indicate more severe disease.
Time frame: At Weeks 2, 4, 8, 16, 20, 24, 32, 40, and 48
Percentage of Participants Achieving Complete Symptomatic Remission by Study Visit
Complete symptomatic remission was defined as an SF subscore = 0 and RB subscore = 0. The SF subscore ranged from 0 to 3 (where 0 = normal number of stools and 3 = at least 5 stools more than normal) and RB subscore ranged from 0 to 3 (where 0 = no blood and 3 = blood alone passes). Higher scores indicate more severe disease.
Time frame: At Weeks 2, 4, 8, 12, 16, 20, 24, 32, 40, 48 and 52
Percentage of Participants Achieving Non-invasive Clinical Response by Study Visit
Non-invasive clinical response was defined as a ≥ 30% decrease from Baseline in composite RB and SF subscores, and a ≥ 1-point decrease from Baseline in RB subscore or RB subscore ≤ 1. The SF subscore ranged from 0 to 3 (where 0 = normal number of stools and 3 = at least 5 stools more than normal) and RB subscore ranged from 0 to 3 (where 0 = no blood and 3 = blood alone passes). The composite RB and SF score range was from 0 to 6, with higher scores indicating more severe disease.
Time frame: At Weeks 2, 4, 8, 12, 16, 20, 24, 32, 40, 48, and 52
Percentage of Participants Achieving Symptomatic Response by Study Visit
Symptomatic response was defined as a ≥ 30% decrease from Baseline in composite RB and SF subscores. The SF subscore ranged from 0 to 3 (where 0= normal number of stools and 3= at least 5 stools more than normal) and RB subscore ranged from 0 to 3 (where 0= no blood and 3= blood alone passes). The composite RB and SF score range was from 0 to 6, with higher scores indicating more severe disease.
Time frame: At Weeks 2, 4, 8, 12, 16, 20, 24, 32, 40, 48, and 52
Percentage of Participants Achieving 4-week Corticosteroid-free Clinical Remission at Week 52 Among Participants Receiving Corticosteroids at Baseline
Four-week corticosteroid-free clinical remission was defined as an SF subscore = 0 (or = 1 with a ≥ 1-point decrease from Baseline), RB subscore = 0, and ES ≤ 1, and have not received corticosteroids for ≥ 4 weeks in the 40-Week Treatment Period. Each component subscore ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.
Time frame: At Week 52
Percentage of Participants Achieving Clinical Remission at Week 52 Among Participants in Clinical Response at Week 12
Clinical remission and clinical response were based on the MMS which is a composite of 3 assessments: SF, RB and ES. Clinical remission was defined as an SF subscore = 0 (or = 1 with a ≥ 1-point decrease from Baseline), RB subscore = 0, and ES ≤ 1 (excluding friability). Clinical response was defined as a ≥ 2-point and ≥ 30% decrease from Baseline MMS, and a ≥ 1-point decrease from Baseline in RB subscore or an absolute RB subscore ≤ 1. Each component subscore ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.
Time frame: At Week 52
Participants with moderately to severely active ulcerative colitis (UC) were enrolled in this study. Eligible participants were randomized in a 2:1 ratio to receive either etrasimod 2 milligrams (mg) once daily or matching placebo once daily for up to 52 weeks.
| Milestone | Etrasimod 2 mg | Placebo |
|---|---|---|
| Started | 289 | 144 |
| Completed | 161 | 46 |
| Not completed | 128 | 98 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Disease worsening | 79 | 73 |
| Withdrew: Physician decision | 2 | 2 |
| Withdrew: Lack of efficacy | 7 | 4 |
| Withdrew: Pregnancy | 2 | 0 |
| Withdrew: Withdrawal by participant or parent/guardian | 24 | 10 |
| Withdrew: Adverse event | 10 | 5 |
| Withdrew: Other | 2 | 2 |
| Withdrew: Lost to follow-up | 1 | 2 |
Clinical remission was based on the modified Mayo score (MMS). The MMS is a composite score of 3 assessments consisting of participant-reported symptoms using daily eDiary and centrally read endoscopy: stool frequency (SF), rectal bleeding (RB) and endoscopic score (ES). Clinical remission was defined as SF subscore = 0 (or = 1 with a ≥ 1-point decrease from Baseline), RB subscore = 0, and ES ≤ 1 (excluding friability). Each component subscore ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.
| Percentage of participants | Etrasimod 2 mg | Placebo |
|---|---|---|
| Percentage of Participants Achieving Clinical Remission at Week 12 | 27.0 | 7.4 |
Clinical remission was based on the MMS which is a composite score of 3 assessments: SF, RB and ES. Clinical remission was defined as SF subscore = 0 (or = 1 with a ≥ 1-point decrease from Baseline), RB subscore = 0, and ES ≤ 1 (excluding friability). Each component subscore ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.
| Percentage of participants | Etrasimod 2 mg | Placebo |
|---|---|---|
| Percentage of Participants Achieving Clinical Remission at Week 52 | 32.1 | 6.7 |
Endoscopic improvement was defined as an ES ≤ 1 (excluding friability). The ES ranged from 0 to 3 (where 0 = normal/inactive disease and 3 = severe disease).
| Percentage of participants | Etrasimod 2 mg | Placebo |
|---|---|---|
| Percentage of Participants Achieving Endoscopic Improvement at Week 12 | 35.0 | 14.1 |
Endoscopic improvement was defined as an ES ≤ 1 (excluding friability). The ES ranged from 0 to 3 (where 0 = normal/inactive disease and 3 = severe disease).
| Percentage of participants | Etrasimod 2 mg | Placebo |
|---|---|---|
| Percentage of Participants Achieving Endoscopic Improvement at Week 52 | 37.2 | 10.4 |
Symptomatic remission was defined as an SF subscore = 0 (or = 1 with a ≥ 1-point decrease from Baseline) and RB subscore = 0. The SF subscore ranged from 0 to 3 (where 0 = normal number of stools and 3 = at least 5 stools more than normal) and RB subscore ranged from 0 to 3 (where 0 = no blood and 3 = blood alone passes). Higher scores indicate more severe disease.
| Percentage of participants | Etrasimod 2 mg | Placebo |
|---|---|---|
| Percentage of Participants Achieving Symptomatic Remission at Week 12 | 46.0 | 21.5 |
Symptomatic remission was defined as an SF subscore = 0 (or = 1 with a ≥ 1-point decrease from Baseline) and RB subscore = 0. The SF subscore ranged from 0 to 3 (where 0 = normal number of stools and 3 = at least 5 stools more than normal) and RB subscore ranged from 0 to 3 (where 0 = no blood and 3 = blood alone passes). Higher scores indicate more severe disease.
| Percentage of participants | Etrasimod 2 mg | Placebo |
|---|---|---|
| Percentage of Participants Achieving Symptomatic Remission at Week 52 | 43.4 | 18.5 |
Mucosal healing was defined as an ES ≤ 1 (excluding friability) with histologic remission measured by a Geboes Index score \< 2.0. The ES ranged from 0 to 3 (where 0 = normal/inactive disease and 3 = severe disease). The Geboes score grading system is a validated score for evaluating histologic disease activity in UC as follows: grade 0 = structural and architectural changes; grade 1 = chronic inflammatory infiltrate; grade 2 = lamina propria neutrophils and eosinophils; grade 3 = neutrophils in the epithelium; grade 4 = crypt destruction; grade 5 = erosions or ulceration. A higher Geboes score indicates more severe disease.
| Percentage of participants | Etrasimod 2 mg | Placebo |
|---|---|---|
| Percentage of Participants With Mucosal Healing at Week 12 | 21.2 | 4.4 |
Mucosal healing was defined as an ES ≤ 1 (excluding friability) with histologic remission measured by a Geboes Index score \< 2.0. The ES ranged from 0 to 3 (where 0 = normal/inactive disease and 3 = severe disease). The Geboes score grading system is a validated score for evaluating histologic disease activity in UC as follows: grade 0 = structural and architectural changes; grade 1 = chronic inflammatory infiltrate; grade 2 = lamina propria neutrophils and eosinophils; grade 3 = neutrophils in the epithelium; grade 4 = crypt destruction; grade 5 = erosions or ulceration. A higher Geboes score indicates more severe disease.
| Percentage of participants | Etrasimod 2 mg | Placebo |
|---|---|---|
| Percentage of Participants With Mucosal Healing at Week 52 | 26.6 | 8.1 |
Corticosteroid-free clinical remission was defined as an SF subscore = 0 (or = 1 with a ≥ 1-point decrease from Baseline), RB subscore = 0, ES ≤ 1 (excluding friability), and have not received corticosteroids for ≥ 12 weeks in the 40-Week Treatment Period. Each component subscore ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.
| Percentage of participants | Etrasimod 2 mg | Placebo |
|---|---|---|
| Percentage of Participants Achieving Corticosteroid-free Clinical Remission at Week 52 | 32.1 | 6.7 |
Sustained clinical remission was defined as an SF subscore = 0 (or = 1 with a ≥ 1-point decrease from Baseline), RB subscore = 0, and ES ≤ 1 (excluding friability) at both Week 12 and Week 52. Each component subscore ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.
| Percentage of participants | Etrasimod 2 mg | Placebo |
|---|---|---|
| Percentage of Participants Achieving Sustained Clinical Remission at Both Weeks 12 and 52 | 17.9 | 2.2 |
Clinical response was based on the MMS which is a composite score of 3 assessments: SF, RB and ES. Clinical response was defined as a ≥ 2-point and ≥ 30% decrease from Baseline MMS, and a ≥ 1-point decrease from Baseline in RB subscore or an absolute RB subscore ≤ 1. Each component subscore ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.
| Percentage of participants | Etrasimod 2 mg | Placebo |
|---|---|---|
| Percentage of Participants Achieving Clinical Response at Week 12 | 62.4 | 34.1 |
Clinical response was based on the MMS which is a composite score of 3 assessments: SF, RB and ES. Clinical response was defined as a ≥ 2-point and ≥ 30% decrease from Baseline MMS, and a ≥ 1-point decrease from Baseline in RB subscore or an absolute RB sub-score ≤ 1. Each component subscore ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.
| Percentage of participants | Etrasimod 2 mg | Placebo |
|---|---|---|
| Percentage of Participants Achieving Clinical Response at Week 52 | 48.2 | 23.0 |
Clinical response was based on the MMS which is a composite score of 3 assessments: SF, RB and ES. Clinical response was defined as a ≥ 2-point and ≥ 30% decrease from Baseline MMS, and a ≥ 1-point decrease from Baseline in RB subscore or an absolute RB subscore ≤ 1. Each component subscore ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.
| Percentage of participants | Etrasimod 2 mg | Placebo |
|---|---|---|
| Percentage of Participants Achieving Clinical Response at Both Weeks 12 and 52 | 44.9 | 18.5 |
Mucosal healing was defined as an ES ≤ 1 (excluding friability) with histologic remission measured by a Geboes Index score \< 2.0. The ES ranged from 0 to 3 (where 0 = normal/inactive disease and 3 = severe disease). The Geboes score grading system is a validated score for evaluating histologic disease activity in UC as follows: grade 0 = structural and architectural changes; grade 1 = chronic inflammatory infiltrate; grade 2 = lamina propria neutrophils and eosinophils; grade 3 = neutrophils in the epithelium; grade 4 = crypt destruction; grade 5 = erosions or ulceration. A higher Geboes score indicates more severe disease.
| Percentage of participants | Etrasimod 2 mg | Placebo |
|---|---|---|
| Percentage of Participants With Mucosal Healing at Both Weeks 12 and 52 | 13.5 | 2.2 |
Endoscopic normalization was defined as an ES = 0. The ES ranged from 0 to 3 (where 0= normal/inactive disease and 3= severe disease).
| Percentage of participants | Etrasimod 2 mg | Placebo |
|---|---|---|
| Percentage of Participants Achieving Endoscopic Normalization at Week 12 | 14.6 | 4.4 |
Endoscopic normalization was defined as an ES = 0. The ES ranged from 0 to 3 (where 0= normal/inactive disease and 3= severe disease).
| Percentage of participants | Etrasimod 2 mg | Placebo |
|---|---|---|
| Percentage of Participants Achieving Endoscopic Normalization at Week 52 | 26.3 | 5.9 |
Endoscopic normalization was defined as an ES = 0. The ES ranged from 0 to 3 (where 0= normal/inactive disease and 3= severe disease).
| Percentage of participants | Etrasimod 2 mg | Placebo |
|---|---|---|
| Percentage of Participants Achieving Endoscopic Normalization at Both Weeks 12 and 52 | 10.6 | 1.5 |
Symptomatic remission was defined as an SF subscore = 0 (or = 1 with a ≥ 1-point decrease from Baseline) and RB subscore = 0. The SF subscore ranged from 0 to 3 (where 0 = normal number of stools and 3 = at least 5 stools more than normal) and RB subscore ranged from 0 to 3 (where 0 = no blood and 3 = blood alone passes). Higher scores indicate more severe disease.
| Percentage of participants | Etrasimod 2 mg | Placebo |
|---|---|---|
| Week 2 | 15.3 | 8.9 |
| Week 4 | 28.1 | 13.3 |
| Week 8 | 37.6 | 20.7 |
| Week 16 | 43.1 | 21.5 |
| Week 20 | 43.8 | 20.0 |
| Week 24 | 44.9 | 23.7 |
| Week 32 | 44.5 | 18.5 |
| Week 40 | 42.0 | 18.5 |
| Week 48 | 42.0 | 15.6 |
Complete symptomatic remission was defined as an SF subscore = 0 and RB subscore = 0. The SF subscore ranged from 0 to 3 (where 0 = normal number of stools and 3 = at least 5 stools more than normal) and RB subscore ranged from 0 to 3 (where 0 = no blood and 3 = blood alone passes). Higher scores indicate more severe disease.
| Percentage of participants | Etrasimod 2 mg | Placebo |
|---|---|---|
| Week 2 | 5.8 | 2.2 |
| Week 4 | 11.3 | 4.4 |
| Week 8 | 16.8 | 6.7 |
| Week 12 | 23.0 | 6.7 |
| Week 16 | 21.2 | 5.9 |
| Week 20 | 22.3 | 4.4 |
| Week 24 | 22.3 | 8.1 |
| Week 32 | 23.0 | 3.0 |
| Week 40 | 21.2 | 5.9 |
| Week 48 | 19.7 | 2.2 |
| Week 52 | 24.5 | 4.4 |
Non-invasive clinical response was defined as a ≥ 30% decrease from Baseline in composite RB and SF subscores, and a ≥ 1-point decrease from Baseline in RB subscore or RB subscore ≤ 1. The SF subscore ranged from 0 to 3 (where 0 = normal number of stools and 3 = at least 5 stools more than normal) and RB subscore ranged from 0 to 3 (where 0 = no blood and 3 = blood alone passes). The composite RB and SF score range was from 0 to 6, with higher scores indicating more severe disease.
| Percentage of participants | Etrasimod 2 mg | Placebo |
|---|---|---|
| Week 2 | 38.3 | 33.3 |
| Week 4 | 56.2 | 39.3 |
| Week 8 | 63.1 | 43.0 |
| Week 12 | 65.7 | 42.2 |
| Week 16 | 55.5 | 30.4 |
| Week 20 | 57.3 | 28.1 |
| Week 24 | 56.6 | 30.4 |
| Week 32 | 54.0 | 25.2 |
| Week 40 | 51.5 | 23.0 |
| Week 48 | 51.1 | 21.5 |
| Week 52 | 50.4 | 23.7 |
Symptomatic response was defined as a ≥ 30% decrease from Baseline in composite RB and SF subscores. The SF subscore ranged from 0 to 3 (where 0= normal number of stools and 3= at least 5 stools more than normal) and RB subscore ranged from 0 to 3 (where 0= no blood and 3= blood alone passes). The composite RB and SF score range was from 0 to 6, with higher scores indicating more severe disease.
| Percentage of participants | Etrasimod 2 mg | Placebo |
|---|---|---|
| Week 2 | 39.4 | 33.3 |
| Week 4 | 57.3 | 40.0 |
| Week 8 | 64.6 | 43.7 |
| Week 12 | 66.4 | 42.2 |
| Week 16 | 55.5 | 31.1 |
| Week 20 | 57.7 | 28.1 |
| Week 24 | 56.9 | 30.4 |
| Week 32 | 54.7 | 25.2 |
| Week 40 | 51.8 | 23.0 |
| Week 48 | 51.5 | 21.5 |
| Week 52 | 50.7 | 23.7 |
Four-week corticosteroid-free clinical remission was defined as an SF subscore = 0 (or = 1 with a ≥ 1-point decrease from Baseline), RB subscore = 0, and ES ≤ 1, and have not received corticosteroids for ≥ 4 weeks in the 40-Week Treatment Period. Each component subscore ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.
| Percentage of participants | Etrasimod 2 mg | Placebo |
|---|---|---|
| Percentage of Participants Achieving 4-week Corticosteroid-free Clinical Remission at Week 52 Among Participants Receiving Corticosteroids at Baseline | 31.0 | 7.5 |
Clinical remission and clinical response were based on the MMS which is a composite of 3 assessments: SF, RB and ES. Clinical remission was defined as an SF subscore = 0 (or = 1 with a ≥ 1-point decrease from Baseline), RB subscore = 0, and ES ≤ 1 (excluding friability). Clinical response was defined as a ≥ 2-point and ≥ 30% decrease from Baseline MMS, and a ≥ 1-point decrease from Baseline in RB subscore or an absolute RB subscore ≤ 1. Each component subscore ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.
| Percentage of participants | Etrasimod 2 mg | Placebo |
|---|---|---|
| Percentage of Participants Achieving Clinical Remission at Week 52 Among Participants in Clinical Response at Week 12 | 49.1 | 17.4 |
Collected over Up to 56 weeks (12-Week and 40-Week Treatment Periods plus Follow-up). Treatment-emergent adverse events (TEAEs) were collected from first dose of study treatment up to 30 days following discontinuation of the study treatment.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Etrasimod 2 mg | 0/289 (0%) | 20/289 (6.9%) | 204/289 (70.6%) |
| Placebo | 0/144 (0%) | 9/144 (6.3%) | 77/144 (53.5%) |
| Event | Etrasimod 2 mg | Placebo |
|---|---|---|
| Colitis ulcerativeGastrointestinal disorders | 6/289 | 3/144 |
| Large intestine perforationGastrointestinal disorders | 0/289 | 1/144 |
| COVID-19 pneumoniaInfections and infestations | 1/289 | 1/144 |
| COVID-19Infections and infestations | 1/289 | 1/144 |
| Campylobacter infectionInfections and infestations | 0/289 | 1/144 |
| CellulitisInfections and infestations | 0/289 | 1/144 |
| AnaemiaBlood and lymphatic system disorders | 2/289 | 1/144 |
| PeritonitisInfections and infestations | 0/289 | 1/144 |
| Mucosal prolapse syndromeGastrointestinal disorders | 1/289 | 0/144 |
| Abdominal painGastrointestinal disorders | 1/289 | 0/144 |
| Event | Etrasimod 2 mg | Placebo |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 24/289 | 14/144 |
| HeadacheNervous system disorders | 24/289 | 7/144 |
| Colitis ulcerativeGastrointestinal disorders | 17/289 | 10/144 |
| COVID-19Infections and infestations | 19/289 | 8/144 |
| DizzinessNervous system disorders | 15/289 | 1/144 |
| PyrexiaGeneral disorders | 14/289 | 6/144 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 13/289 | 3/144 |
| Abdominal painGastrointestinal disorders | 11/289 | 5/144 |
| NauseaGastrointestinal disorders | 9/289 | 2/144 |
| NasopharyngitisInfections and infestations | 3/289 | 4/144 |
Full Analysis Set (FAS): All randomized participants who received at least 1 dose of study treatment.
| Age, Categorical(Participants) | Etrasimod 2 mg | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 1 | 1 |
| Between 18 and 65 years | 272 | 133 | 405 |
| >=65 years | 17 | 10 | 27 |
| Age, Continuous(Years) | Etrasimod 2 mg | Placebo | Total |
|---|---|---|---|
| Mean | 41.2 ± 13.97 | 38.9 ± 14.04 | 40.4 ± 14.02 |
| Sex: Female, Male(Participants) | Etrasimod 2 mg | Placebo | Total |
|---|---|---|---|
| Female | 137 | 56 | 193 |
| Male | 152 | 88 | 240 |
| Ethnicity (NIH/OMB)(Participants) | Etrasimod 2 mg | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 12 | 7 | 19 |
| Not Hispanic or Latino | 275 | 136 | 411 |
| Unknown or Not Reported | 2 | 1 | 3 |
| Race (NIH/OMB)(Participants) | Etrasimod 2 mg | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 3 | 4 |
| Asian | 22 | 9 | 31 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 6 | 3 | 9 |
| White | 256 | 129 | 385 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 4 | 0 | 4 |
Showing the first 100 of 315 sites across 40 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2019 to primary completion in Feb 2022, 31 months.
Results were first posted in Dec 2022, 10 months after primary completion.
Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's 31 months is below that.
Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Etrasimod